ScienceDex / Researcher record
Michael J Brownstein
- Myosin Therapeutics Inc. (no department on record)
From the FY2025 NIH awards this investigator leads as contact PI. The department is the award's.
Start from a Word CV, PubMed IDs or ORCID.
- Early Career
NIH Funding · FY2025
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2025 | $2,495,219 | 2 | #4,652 |
| 2026 | $2,241,448 | 1 | #9,168 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY2025 · selected2 records
- FY20261 record
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 10123302Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2025 through FY2026Career claims are limited to the years shown.
FY2025 award records by amount
NIH award records listing Michael J Brownstein as a PI. Multi-PI records show the full award amount for context.
- 2R44CA278293-04R44Contact PIPhase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas$2.2Maward amount
- 1SB1CA302068-01SB1Contact PIDevelopment of drug product to support a Phase 0/1b dose escalation trial of MT-125 in recurrent high grade gliomas$249.4Kaward amount
Award organization
Organizations that administered FY2025 awards listing Michael J Brownstein as a PI.
FY2025 award administered by Myosin Therapeutics Inc. (FL).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2025First NIH AwardMyosin Therapeutics Inc.
- 2025$500K Cumulative Funding
- 2025$1M Cumulative Funding
- 2025$2M Cumulative Funding
- 2025Entered Top 50% NationallyRanked #4652
- 2025Entered Top 25% NationallyRanked #4652